Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Pulmonx history
Pulmonx company history timeline
Used together, these technologies have been clinically proven to improve pulmonary function, exercise capacity, and quality of life in emphysema patients across multiple randomized controlled trials and in more than 19,000 patients worldwide since 2007.
In the United States, COPD is the third leading cause of death and affected approximately 16 million Americans as of 2013.27
In 2015, it affected approximately 175 million patients and was responsible for 3.2 million deaths globally.26
The Zephyr® Valve was granted breakthrough status and approved by the FDA in June 2018, because according to the FDA it “represents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks.
As of 2018, approximately 3.8 million patients in the United States were diagnosed with emphysema,31 of which roughly 1.5 million have severe emphysema.32
Age at Treatment: 71Hospital: Lung Center and Intensive Care Services, Penn Highlands DuboisDate of Procedure: February 2019
COPD is expected to be associated with approximately $49 billion in direct medical costs in 2020.28
Rate Pulmonx's efforts to communicate its history to employees.
Pulmonx jobs
Do you work at Pulmonx?
Does Pulmonx communicate its history to new hires?
Pulmonx history FAQs
Zippia gives an in-depth look into the details of Pulmonx, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Pulmonx. The employee data is based on information from people who have self-reported their past or current employments at Pulmonx. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Pulmonx. The data presented on this page does not represent the view of Pulmonx and its employees or that of Zippia.
Pulmonx may also be known as or be related to PULMONX, Pulmonx, Pulmonx Corp, Pulmonx Corp. and Pulmonx Corporation.